Multisystem inflammatory syndrome in children: another COVID-19 sequel

Area of Science:

• Pediatric infectious diseases
• Immunology
• Epidemiology

Background:

• The COVID-19 pandemic has revealed significant health consequences in children.
• While often mild, SARS-CoV-2 infection can trigger severe hyperinflammation and multi-organ dysfunction.
• Multisystem inflammatory syndrome in children (MIS-C) is a critical post-infectious complication demanding global attention.

Purpose of the Study:

• To comprehensively review the epidemiology of MIS-C.
• To discuss the proposed pathophysiological mechanisms underlying MIS-C.
• To evaluate the diverse clinical manifestations and current treatment approaches for MIS-C.

Main Methods:

• Systematic literature review of MIS-C cases and research.
• Analysis of epidemiological data on MIS-C incidence and demographics.
• Synthesis of findings on proposed pathogenesis, clinical presentations, and therapeutic interventions.

Main Results:

• MIS-C exhibits varied epidemiology globally, with distinct clinical profiles.
• Pathogenesis likely involves aberrant immune responses post-viral infection.
• Clinical presentations range from fever and rash to severe cardiac and gastrointestinal involvement.
• Treatment strategies are evolving, with corticosteroids and immunomodulators frequently used.

Conclusions:

• MIS-C represents a significant pediatric challenge linked to COVID-19.
• Further research is crucial to elucidate definitive pathogenesis and standardize treatment protocols.
• Effective management requires a multidisciplinary approach, integrating clinical and immunological insights.